Published in Open Cardiovasc Med J on August 10, 2012
Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci (2015) 0.76
Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients (2017) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis (2001) 4.44
Lipotoxicity: when tissues overeat. Curr Opin Lipidol (2003) 4.20
Vitamin E, antioxidant and nothing more. Free Radic Biol Med (2007) 3.87
Epidemiology of non-alcoholic fatty liver disease. Dig Dis (2010) 3.44
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2012) 2.74
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol (2010) 2.63
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract (2010) 2.12
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia (2012) 1.98
Experimental production of gross atherosclerosis in the rat. J Exp Med (1956) 1.84
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr (2012) 1.82
Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev (2008) 1.82
Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2007) 1.76
High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J (2009) 1.63
Nonalcoholic fatty liver disease in India - a lot done, yet more required! Indian J Gastroenterol (2010) 1.60
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol (2011) 1.48
Nonalcoholic fatty liver disease. J Lipid Res (2008) 1.47
Rodent obesity models: an overview. Exp Clin Endocrinol Diabetes (2001) 1.46
A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes (2006) 1.36
Diet-induced changes in serum transaminase and triglyceride levels in healthy adult men. Role of sucrose and excess calories. Am J Med (1983) 1.36
Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile. J Pediatr Gastroenterol Nutr (2007) 1.33
Regulation of hepatic 7 alpha-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem (1995) 1.33
Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. J Leukoc Biol (2008) 1.19
Experimental obesity. I. Production of obesity in rats by feeding high-fat diets. J Nutr (1955) 1.14
Vitamin E: action, metabolism and perspectives. J Physiol Biochem (2001) 1.08
The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta (1995) 1.08
Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther (2008) 1.06
The protection by ascorbate and glutathione against microsomal lipid peroxidation is dependent on vitamin E. Eur J Biochem (1988) 1.05
Time course of the development of non-alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats. Br J Nutr (2006) 1.05
Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2006) 1.04
Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. Am J Physiol Endocrinol Metab (2004) 1.02
Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Eur J Pharmacol (2008) 0.97
Effects of N-acetylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur J Pharmacol (2006) 0.97
Effect of dietary fat to produce non-alcoholic fatty liver in the rat. J Gastroenterol Hepatol (2009) 0.96
The low-density lipoprotein receptor and cholesterol synthesis are affected differently by dietary cholesterol in the rat. Biochim Biophys Acta (1993) 0.96
Nascent hepatic lipoproteins in hypothyroid rats. J Lipid Res (1983) 0.96
The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit. Br J Clin Pharmacol (2004) 0.95
A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice. Exp Mol Pathol (2011) 0.94
Gene expression in livers of BALB/C and C57BL/6J mice fed a high-fat diet. Toxicol Pathol (2011) 0.93
Plasma lipid composition and LDL oxidation. Clin Chem Lab Med (2003) 0.92
Effects of cysteine-containing compounds on biosynthesis of triacylglycerol and cholesterol and anti-oxidative protection in liver from mice consuming a high-fat diet. Br J Nutr (2007) 0.92
Improvement in high-fat diet-induced obesity and body fat accumulation by a Nelumbo nucifera leaf flavonoid-rich extract in mice. J Agric Food Chem (2010) 0.91
Sesame as a hypocholesteraemic and antioxidant dietary component. Food Chem Toxicol (2008) 0.91
Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol (2009) 0.89
High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatol Res (2011) 0.88
Centrolobular liver fibrosis in the hypercholesterolemic rabbit. Hepatology (1996) 0.88
Pediatric nonalcoholic fatty liver disease. Gastroenterol Nurs (2008) 0.87
Heart and blood pressure adaptations in Wistar rats fed with different high-fat diets for 18 months. Nutrition (2003) 0.87
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med (2011) 0.86
Lipid profile of rats fed high-fat diets based on flaxseed, peanut, trout, or chicken skin. Nutrition (2006) 0.86
Dietary lipids coinduce xenobiotic metabolizing enzymes in rat liver. Biochim Biophys Acta (1993) 0.85
Age-related changes in cholesterol and bile acid metabolism in rats. J Lipid Res (1978) 0.84
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 0.83
Non-alcoholic fatty liver disease: a brief review. Scand J Gastroenterol Suppl (2004) 0.82
Effect of dietary lipids on levels of UDP-glucuronosyltransferase in liver. Biochem Pharmacol (1992) 0.81
Dietary lipids and NAFLD: suggestions for improved nutrition. Acta Gastroenterol Belg (2011) 0.80
Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B (2006) 0.80
Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity. Fed Proc (1986) 0.80
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro. Eur J Med Chem (2011) 0.79
High-fat sunflower and olive oil diets affect serum lipid levels in steatotic rat liver differently. J Nutr Sci Vitaminol (Tokyo) (1997) 0.79
Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol (2011) 0.79
[Effects of high-fat diet on blood lipids in rats]. Wei Sheng Yan Jiu (2011) 0.78
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology (2011) 0.78
Role of pancreatic-derived factor in type 2 diabetes: evidence from pancreatic β cells and liver. Nutr Rev (2012) 0.77
Influence of dietary fats on weight gain in albino rats. Indian J Physiol Pharmacol (2005) 0.77
The effect of L-arginine or L-citrulline supplementation on biochemical parameters and the vascular aortic wall in high-fat and high-cholesterol-fed rats. Cell Biochem Funct (2011) 0.77
Antihyperlipidemic activities of Pleurotus ferulae on biochemical and histological function in hypercholesterolemic rats. J Res Med Sci (2011) 0.77
Effects of ID-alG™ on weight management and body fat mass in high-fat-fed rats. Phytother Res (2011) 0.76
Nonalcoholic fatty liver disease: pharmacologic and surgical options. Gastroenterol Clin North Am (2011) 0.76
Significance of low serum urea nitrogen concentrations. Clin Chem (1989) 0.76
Effect of dietary fat on serum and tissue lipids of adult rats. J Egypt Public Health Assoc (1992) 0.76
[Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development]. Pol Arch Med Wewn (2005) 0.76
TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res (2011) 4.54
Encoding of conditioned fear in central amygdala inhibitory circuits. Nature (2010) 4.29
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res (2013) 2.32
Rosacea: a clinicopathological approach. Dermatology (2004) 2.20
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Time for new indications for statins? Med Sci Monit (2009) 1.87
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol (2006) 1.56
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol (2006) 1.52
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Hypoxemic reperfusion after 120 mins of intestinal ischemia attenuates the histopathologic and inflammatory response. Crit Care Med (2004) 1.50
In vivo aortic valve thermal heterogeneity in patients with nonrheumatic aortic valve stenosis the: first in vivo experience in humans. J Am Coll Cardiol (2008) 1.49
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol (2005) 1.43
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral Oncol (2006) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol (2009) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol (2009) 1.17
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol (2008) 1.13
The influence of platelet-rich plasma on angiogenesis during the early phase of tendon healing. Foot Ankle Int (2009) 1.13
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol (2007) 1.09
"Is obesity linked to aging?": adipose tissue and the role of telomeres. Ageing Res Rev (2011) 1.09
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol (2008) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology (2004) 1.08
Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol (2007) 1.08
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clin Ophthalmol (2011) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Novel mutations and repeated findings of mutations in familial Alzheimer disease. Neurogenetics (2005) 1.07
Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol (2008) 1.06
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Serum uric acid as an independent predictor of early death after acute stroke. Circ J (2007) 1.06
The effect of platelet-rich plasma gel in the early phase of patellar tendon healing. Arch Orthop Trauma Surg (2009) 1.06
Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol (2013) 1.06
Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol (2008) 1.06
Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine (2007) 1.05
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer (2006) 1.04
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res (2009) 1.03
Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int (2005) 1.03
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother (2011) 1.01
Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol (2002) 1.01
Analysis of PRNP gene codon 129 polymorphism in the Greek population. Eur J Epidemiol (2006) 1.01
Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des (2007) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Cranioectodermal dysplasia: a probable ciliopathy. Am J Med Genet A (2009) 1.01
Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des (2011) 1.01
Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology (2013) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis. Med Oncol (2010) 1.01